The Business Research Company’s Anti-Infective Drugs Global Market Report 2021: COVID-19 Implications And Growth to 2030

Pfizer Inc. acquired Amplyx Pharmaceuticals, Inc, an anti-infective therapy-focused privately held company, in an undisclosed financial deal. The deal helps Pfizer to make progress in the development of novel antifungal therapeutics and thereby increase Pfizer’s market share among anti-infectives. Under the terms of the agreement, Pfizer has secured ownership of Amplyx’s potential antiviral and antifungal pipeline drugs, including the lead compound Fosmanogepix (APX001), a novel investigational asset for the treatment of invasive fungal infections. Fosmano

gepix has a novel mechanism of action with the potential to target fungal strains that are resistant to standard of care therapy, thus gaining prominence in lieu of antifungal resistance.

According to the Global Market Model competitive intelligence platform, major players in the anti-infective drug market are strategically partnering and collaborating with other companies to broaden their products and services.

Key competitor market shares in the global anti-infective drugs market, 2020, USD billion

Within the global infectious drugs market, the top six companies accounted for more than 30% of the market in 2020. The market is fragmented with only one player, Gilead, constituting around 16% share of the market and the remaining major players each contribute to less than 5% share of the market. Pfizer had a 2% share of the market in 2020, and the current deal helps increase its market share.

Globally, infectious diseases are responsible for more than 8.4 million deaths annually, accounting for two of the World Health Organization’s top ten causes of death worldwide (WHO). More than 1.5 million cases of invasive fungal infections occur worldwide each year, with mortality rates as high as 30-80% across infection types.

The market remains stable and opportunistic according to The Business Research Company’s research on the anti-infective drugs market. As per data on the Global Market Model, the global anti-infective drugs market size has grown from $106.5 billion in 2019 to $139.3 billion in 2020 at a compound annual growth rate (CAGR) of 30.8%. Further, the market is expected to decline in 2021 to reach 116.4 billion and then grow at a CAGR of 8% to reach $158.29 billion by 2025. The significant growth is mainly due to the COVID-19 outbreak and the huge demand for anti-viral and antibiotic drugs. The enormous demand for antiviral drugs and antibiotic drugs such as Azithromycin, Chloroquine, Acyclovir, and Ribavirin among others have contributed to the overall market growth of anti-infective drugs.

Global, Anti-Infective Drugs Market, Forecast Market Size, 2010 – 2030, $ Billion

“The COVID-19 pandemic has been a stark reminder of the devastating impact of infectious diseases, highlighting the continuous need for new anti-infective therapies to treat both emerging and difficult to treat bacterial, viral, and fungal infections,” said Angela Lukin, Global President, Pfizer Hospital.

The Anti Infective Drugs Global Market Report is one of a series of new reports from The Business Research Company that provides anti-infective drugs market overviews, analyzes and forecasts anti-infective drugs market size, share, anti-infective drugs market players, anti-infective drugs market segments and geographies, the market’s leading competitors’ revenues, profiles and market shares.

Here are some related reports:

Antifungals Global Market Report 2021: COVID 19 Impact and Recovery to 2030

Antimicrobial Susceptibility Testing Global Market Report 2020-30: COVID-19 Growth And Change

 About The Author

Ravikiran has 12 years of research experience in Biotechnology. He extensively worked with such companies/institutions as Ernst and Young (EY), DuPont and Center For Cellular & Molecular Biology (CCMB), Hyderabad. Ravikiran holds bachelor’s and master’s degrees in Biotechnology and Certification in Clinical Research from the Institute of Clinical Research India (ICRI). In 2006, he took an advanced course in Bioinformatics at the Indian Institute of Chemicals Technology (IICT). Some of the clients he has worked for include Asahi Kasei Corporation, Fujifilm, and Sanofi Aventis. At TBRC, key projects he was involved in include a market study for bovine mastitis detection kits and research on multivalent pediatric vaccines.

About The Global Market Model

The Global Market Model is the world’s most comprehensive database of integrated market information available. The ten-year forecasts in the Global Market Model are updated in real time to reflect the latest market realities, which is a huge advantage over static, report-based platforms.

Interested In Knowing More About The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. The Global Market Model is The Business Research Company’s flagship product.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company

Follow us on Twitter: https://twitter.com/tbrc_info